Hodgkin's lymphoma Posts on Medivizor
Navigation Menu

Hodgkin’s lymphoma Posts on Medivizor

Vacations for Adult Cancer Patients: Update

Vacations for Adult Cancer Patients: Update

Posted by on Mar 4, 2022 in Blog, Breast cancer, Colorectal cancer, Hodgkin's lymphoma, Leukemia, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Non-Hodgkin lymphoma, Prostate cancer | 0 comments

Two of our most popular previous blog posts described free vacation opportunities for adults with cancer. Given the uncertainty of the past two years, we thought it was time for an update.  Here is a short list of organizations that have made it their mission to provide needed respite to those affected by cancer. Each has been verified to have...

Read More

Investigating the risk of thyroid disorders in survivors of Hodgkin lymphoma.

Investigating the risk of thyroid disorders in survivors of Hodgkin lymphoma.

Posted by on Dec 31, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the risk of developing a range of thyroid disorders in both childhood and adult-treated female survivors of Hodgkin lymphoma (HL). The data showed that the risk of developing thyroid disorders increased significantly over time in both childhood and adult-treated survivors of HL. Some background Hodgkin lymphoma...

Read More

Comparing the health-related quality of life outcomes between pembrolizumab and brentuximab vedotin in patients with relapsed or refractory classical Hodgkin lymphoma.

Comparing the health-related quality of life outcomes between pembrolizumab and brentuximab vedotin in patients with relapsed or refractory classical Hodgkin lymphoma.

Posted by on Dec 5, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study compared the health-related quality of life (HR-QoL) outcomes between pembrolizumab (Keytruda) and brentuximab vedotin (BV; Adcetris) in patients with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). The data showed that the pembrolizumab improved the HR-QoL outcomes compared to BV in these patients. Some...

Read More

Is radiotherapy useful for the treatment of advanced Hodgkin lymphoma with bulky sites previously exposed to ABVD?

Is radiotherapy useful for the treatment of advanced Hodgkin lymphoma with bulky sites previously exposed to ABVD?

Posted by on Nov 14, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the potential benefits of radiotherapy (RT) for the treatment of patients with advanced-stage Hodgkin lymphoma (HL) who have achieved a complete metabolic response (CMR) after ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)-based chemotherapy. The data showed no significant difference in patient outcomes...

Read More

Evaluating infection risk in patients with blood cancers treated with new targeted therapy drugs

Evaluating infection risk in patients with blood cancers treated with new targeted therapy drugs

Posted by on Nov 14, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to investigate the risk of infections in patients with blood cancers who were treated with new biological therapy drugs.  This study concluded that a high proportion of these patients experienced severe infections. However, the infection risk was similar to that of chemotherapy.   Some background...

Read More

Combining brentuximab vedotin and bendamustine for the treatment of children with relapsed/refractory Hodgkin Lymphoma

Combining brentuximab vedotin and bendamustine for the treatment of children with relapsed/refractory Hodgkin Lymphoma

Posted by on Nov 7, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to evaluate brentuximab vedotin (BV; Adcedris) and bendamustine (Treanda) treatment in pediatric patients with relapsed/refractory (r/r) Hodgkin Lymphoma (HL).  This study concluded that this treatment combination was safe and effective in these patients.   Some background HL is a common cancer...

Read More

Investigating the side effect profiles of different PD-L1/PD-1 inhibitor-based combination therapies.

Investigating the side effect profiles of different PD-L1/PD-1 inhibitor-based combination therapies.

Posted by on Nov 7, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the side effect profiles of different PD-1/PD-L1 inhibitor-based combination therapies. The data showed that PD-1/PD-L1 inhibitors in combination with chemotherapy were associated with a higher risk of treatment-related side effects than with targeted therapy or immunotherapy combinations. Some background...

Read More

Evaluating anti-CD25 radioimmunotherapy with BEAM autologous stem cell transplantation in patients with high-risk relapsed or refractory classical Hodgkin lymphoma

Evaluating anti-CD25 radioimmunotherapy with BEAM autologous stem cell transplantation in patients with high-risk relapsed or refractory classical Hodgkin lymphoma

Posted by on Oct 31, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell The authors compared the safety and effectiveness of 90Y-antiCD25 (yttrium 90 basiliximab; aTac) radioimmunotherapy (RAI), followed by BEAM (carmustine, etoposide, cytarabine, melphalan) and autologous stem cell transplantation (ASCT) for the treatment of patients with high-risk relapsed or refractory (r/r) classical Hodgkin...

Read More

Evaluating the clinical outcomes in patients with relapsed or refractory classical Hodgkin lymphoma after first-line treatment.

Evaluating the clinical outcomes in patients with relapsed or refractory classical Hodgkin lymphoma after first-line treatment.

Posted by on Oct 31, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the characteristics, treatment patterns, and outcomes of patients with relapsed or refractory (r/r) classical Hodgkin lymphoma (HL) after treatment with first-line therapy.  Some background HL is a cancer of white blood cells. Most patients with HL respond to first-line chemotherapy regimens. However, up to...

Read More

Reviewing treatment options and outcomes for older patients with classic Hodgkin lymphoma

Reviewing treatment options and outcomes for older patients with classic Hodgkin lymphoma

Posted by on Oct 9, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated treatment options and outcomes for older patients with classic Hodgkin lymphoma (HL). This study concluded that conventional chemotherapy regimens remain a standard of care for these patients. Some background Chemotherapy remains the standard first-line treatment for cHL. One of the most commonly used regimens...

Read More

Does radiotherapy reduce the risk of recurrence in patients with early-stage Hodgkin lymphoma?

Does radiotherapy reduce the risk of recurrence in patients with early-stage Hodgkin lymphoma?

Posted by on Sep 12, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study looked at whether radiotherapy had an impact on the recurrence rate in patients with early-stage Hodgkin lymphoma (HL). It found that in patients with early-stage HL who responded fully to chemotherapy, the addition of radiotherapy reduced the risk of localized recurrence.  Some background Early-stage...

Read More